Hall Laurie J Trustee Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Hall Laurie J Trustee reduced its stake in AbbVie Inc by 2.85% during the most recent quarter end. The investment management company now holds a total of 57,143 shares of AbbVie Inc which is valued at $3,701,152 after selling 1,678 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Jul 12, 2016.AbbVie Inc makes up approximately 2.39% of Hall Laurie J Trustee’s portfolio.

Other Hedge Funds, Including , Keel Point added ABBV to its portfolio by purchasing 6,501 company shares during the most recent quarter which is valued at $421,070. AbbVie Inc makes up approx 0.18% of Keel Point’s portfolio.Dnb Asset Management As reduced its stake in ABBV by selling 68,586 shares or 33.39% in the most recent quarter. The Hedge Fund company now holds 136,795 shares of ABBV which is valued at $8,776,767. AbbVie Inc makes up approx 0.18% of Dnb Asset Management As’s portfolio.Stokes Hubbell Capital Management reduced its stake in ABBV by selling 92 shares or 0.26% in the most recent quarter. The Hedge Fund company now holds 34,761 shares of ABBV which is valued at $2,230,266. AbbVie Inc makes up approx 0.95% of Stokes Hubbell Capital Management’s portfolio.Toth Financial Advisory Corp boosted its stake in ABBV in the latest quarter, The investment management firm added 10,137 additional shares and now holds a total of 34,583 shares of AbbVie Inc which is valued at $2,168,700. AbbVie Inc makes up approx 0.66% of Toth Financial Advisory Corp’s portfolio.

AbbVie Inc closed down -0.3 points or -0.47% at $63.32 with 88,27,486 shares getting traded on Friday. Post opening the session at $63.82, the shares hit an intraday low of $63.13 and an intraday high of $64.17 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.